China healthcare: greying population, golden opportunity

China's healthcare sector is being driven by China's rapidly expanding aged population.

by China Equities team 15 Feb 2018

China healthcare: greying population, golden opportunity – in 60 seconds

  • China's aging population means 115 million more people aged 65+ by 2030, according to the United Nations;
  • China's healthcare system will face many more cases of age-associated conditions and chronic disease as China's population ages;
  • China's healthcare sector and system will benefit as public and private healthcare spending grows;
  • Chinese healthcare companies are increasing R&D spending to develop innovative pharmaceutical drugs and treatments;
  • We see good growth prospects in China's healthcare sector and we are focusing on the most innovative companies with the best long-term prospects

China's elderly population: how quickly is it growing?

With more than six times the total in Japan and three times that in the US, China's estimated population of 245.9 million people aged 65+ in 2030 will be the world's largest, according to UN forecasts (1).

While the 65+ population will be huge in 2030, it will get there at a rapid rate. 115 million more people will be aged over 65 in China by 2030, and that means annual growth of 4.2%, almost double the 2.3% rate recorded between 2000 and 2015.

115 million more people will be aged over 65 in China by 2030

How will China's aged population compare with other countries by 2030

Source: United Nations Population Division: World Population Prospects 2017.

How is China's aging population affecting the healthcare sector?

This rapid growth and the sheer size of the 65+ demographic means more cases of age-associated conditions, such as mobility, vision, and hearing impairment, plus a greater number of chronic disease cases, such as diabetes and hypertension, according to the World Health Organization (2)

Taking diabetes as an example, 150.6 million Chinese are expected to have it by 2040, a 37% increase on 2015, and total expenditure on care and treatments will reach an estimated USD 71.8 billion, up from USD 51 billion in 2015, according to estimates by the International Diabetes Federation (3).

Is healthcare spending growing in China?

China's government is stepping up investment in healthcare services, with total spending increasing by a factor of five between 2004 and 2014 (4), according to World Health Organization (WHO) data (4), as it has built facilities and increased the supply of medical services.

A further source of demand for healthcare comes from Chinese citizens' increasing spending on medical services. As incomes rise and healthcare options increase, consumers are spending more on private healthcare, with total private spending growing an estimated 16.4% per year between 2005 and 2014, according to WHO data (4).

And while the rates of both public and private health expenditure are growing fast, there is still significant room for growth because actual healthcare spending levels in China remain low by international standards, with healthcare spending in estimated at 5.5% of GDP in 2014, compared with 10.2% in Japan, and 17.1% in the US, according to WHO data.

Watch Bin Shi talk about China's healthcare sector here

How are Chinese healthcare companies responding to China's aging population?

While underlying macro trends are positive for the healthcare sector as a whole, competition is fierce, and that means Chinese companies have to innovate to take a share of the market.

Indeed, because of the size of the opportunity, and competition for sales, Chinese companies are boosting their R&D investments to create innovative products.

Chinese companies are innovating. Fast.

And this is creating a boom in new and innovative drug patents being produced by Chinese companies.

In 2015, Chinese firms registered 855 new pharmaceutical patents (5), up 151.4% compared with 2007 and outstripping growth in other global markets.

With recent reforms to speed up patent approval processes, we are expecting a strong pipeline of innovative products in the future.

What does China's aging population mean for investors in the healthcare sector?

So, with China's growing aged population, plus increasing spending on medical services, the long-term outlook looks strong for China's healthcare sector.

But innovation will be key, since competition is ratcheting up, and only companies with a strong innovative culture will be best set to capitalize on the undoubted opportunities in the sector.

Read more


Equity investments from a global player

UBS Asset Management in the United States

The website contains general information about UBS Asset Management (Americas), Inc., UBS Hedge Fund Solutions LLC, and UBS O'Connor LLC, collectively known as "UBS Asset Management". The information contained on this website does not constitute investment advice or a recommendation to purchase or sell any securities or other financial instrument or any particular strategy or fund. Market commentary, product information and related performance data available on this website has been compiled from sources believed to be reliable and is provided in good faith for informational purposes only. UBS Asset Management does not guarantee the accuracy, suitability or completeness of information contained on this website, and all such information, including but not limited to performance data and related metrics, is subject to change without notice. Certain content on this website is intended for institutional investors and their financial representatives only, and should not be relied upon by retail investors or members of the general public.

Market commentary and similar statements contained herein are based on current expectations and may be considered “forward-looking statements.” Actual future results, however, may prove to be different from expectations. The opinions expressed are a reflection of UBS Asset Management’s best judgment at the time of posting, and any obligation to update or alter any forward-looking statement as a result of new information, future events, or otherwise is disclaimed.

Investments involve risks, are not guaranteed and may not return the original principal amount invested. Past performance is no guarantee of future results. Investors should read all available product information carefully before making an investment decision, including information about applicable risks, fees and expenses. This website does not address the investment objectives, risk tolerance or financial needs of any particular investor. In addition, any statements regarding investment performance expectations, risk and/or return targets do not constitute a representation or warranty that such expectations or targets will be achieved.

This website is not intended for persons located in any jurisdiction where the availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirement in any such jurisdiction.

Please confirm you are a US resident to proceed.

Please select at least 1 checkbox